Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

Similar articles for PubMed (Select 23404097)

1.

A study of financial incentives to reduce plasma HIV RNA among patients in care.

Farber S, Tate J, Frank C, Ardito D, Kozal M, Justice AC, Scott Braithwaite R.

AIDS Behav. 2013 Sep;17(7):2293-300. doi: 10.1007/s10461-013-0416-1.

2.

Conditional economic incentives to improve HIV treatment adherence: literature review and theoretical considerations.

Galárraga O, Genberg BL, Martin RA, Barton Laws M, Wilson IB.

AIDS Behav. 2013 Sep;17(7):2283-92. doi: 10.1007/s10461-013-0415-2. Review.

3.

"Payment by Results"--financial incentives and motivational interviewing, adherence interventions in young adults with perinatally acquired HIV-1 infection: a pilot program.

Foster C, McDonald S, Frize G, Ayers S, Fidler S.

AIDS Patient Care STDS. 2014 Jan;28(1):28-32. doi: 10.1089/apc.2013.0262.

PMID:
24428797
4.

Cost ramifications of increased reporting of detectable plasma HIV-1 RNA levels by the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 version 1.0 viral load test.

Willig JH, Nevin CR, Raper JL, Saag MS, Mugavero MJ, Willig AL, Burkhardt JH, Schumacher JE, Johnson VA.

J Acquir Immune Defic Syndr. 2010 Aug;54(4):442-4. doi: 10.1097/QAI.0b013e3181d01d1d. No abstract available.

5.

Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.

Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D.

J Acquir Immune Defic Syndr. 2001 May 1;27(1):14-9.

PMID:
11404515
6.

The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study.

Laurent C, Diakhaté N, Gueye NF, Touré MA, Sow PS, Faye MA, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E.

AIDS. 2002 Jul 5;16(10):1363-70.

PMID:
12131213
7.

Impact of use of alcohol and illicit drugs by AIDS patients on adherence to antiretroviral therapy in Bahia, Brazil.

Teixeira C, Dourado Mde L, Santos MP, Brites C.

AIDS Res Hum Retroviruses. 2013 May;29(5):799-804. doi: 10.1089/AID.2012.0296. Epub 2013 Feb 5.

PMID:
23294471
8.

Cost-effectiveness of nurse-led versus doctor-led antiretroviral treatment in South Africa: pragmatic cluster randomised trial.

Barton GR, Fairall L, Bachmann MO, Uebel K, Timmerman V, Lombard C, Zwarenstein M.

Trop Med Int Health. 2013 Jun;18(6):769-77. doi: 10.1111/tmi.12093. Epub 2013 Mar 11.

9.

Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.

Hill AM, Clotet B, Johnson M, Stoll M, Bellos N, Smets E.

Pharmacoeconomics. 2010;28 Suppl 1:69-81. doi: 10.2165/11587460-000000000-00000.

PMID:
21182345
10.

Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial.

Weber R, Christen L, Christen S, Tschopp S, Znoj H, Schneider C, Schmitt J, Opravil M, Günthard HF, Ledergerber B; Swiss HIV Cohort Study.

Antivir Ther. 2004 Feb;9(1):85-95.

PMID:
15040540
11.

Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads.

Kolber MA, Gabr AH, De La Rosa A, Glock JA, Jayaweera D, Miller N, Dickinson GM.

AIDS. 2002 Mar 8;16(4):537-42.

PMID:
11872996
12.

Effect of adherence to newly initiated antiretroviral therapy on plasma viral load.

Gross R, Bilker WB, Friedman HM, Strom BL.

AIDS. 2001 Nov 9;15(16):2109-17.

PMID:
11684930
13.

Improved virological suppression in children on antiretroviral treatment receiving community-based adherence support: a multicentre cohort study from South Africa.

Fatti G, Shaikh N, Eley B, Grimwood A.

AIDS Care. 2014 Apr;26(4):448-53. doi: 10.1080/09540121.2013.855699. Epub 2013 Nov 11.

PMID:
24215157
14.

Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.

Nolan S, Milloy MJ, Zhang R, Kerr T, Hogg RS, Montaner JS, Wood E.

AIDS Care. 2011 Aug;23(8):980-7. doi: 10.1080/09540121.2010.543882.

PMID:
21480010
15.

Voucher incentives improve linkage to and retention in care among HIV-infected drug users in Chennai, India.

Solomon SS, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS, Balakrishnan P, Mehta SH, Solomon S, Lucas GM.

Clin Infect Dis. 2014 Aug 15;59(4):589-95. doi: 10.1093/cid/ciu324. Epub 2014 May 6.

16.

How reliable is an undetectable viral load?

Combescure C, Vallier N, Ledergerber B, Cavassini M, Furrer H, Rauch A, Battegay M, Bernasconi E, Vernazza P, Hirschel B; Swiss HIV Cohort Study.

HIV Med. 2009 Sep;10(8):470-6. doi: 10.1111/j.1468-1293.2009.00714.x. Epub 2009 May 6.

PMID:
19459990
17.

Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.

Cook J, Dasbach E, Coplan P, Markson L, Yin D, Meibohm A, Nguyen BY, Chodakewitz J, Mellors J.

AIDS Res Hum Retroviruses. 1999 Apr 10;15(6):499-508.

PMID:
10221527
18.

Health literacy, antiretroviral adherence, and HIV-RNA suppression: a longitudinal perspective.

Paasche-Orlow MK, Cheng DM, Palepu A, Meli S, Faber V, Samet JH.

J Gen Intern Med. 2006 Aug;21(8):835-40.

19.

Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.

Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, McCarthy N, Morris L, Walker BD, Goulder P.

AIDS. 2008 Jul 11;22(11):1333-43. doi: 10.1097/QAD.0b013e32830437df.

PMID:
18580613
20.

Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection.

Mauskopf J, Brogan AJ, Talbird SE, Martin S.

AIDS. 2012 Jan 28;26(3):355-64. doi: 10.1097/QAD.0b013e32834e87e6.

PMID:
22089378
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk